GlassScriptPhysician profile
Nirav P Chiniwalla
NPI 1114955291
$11,962.34
in general payments reported to CMS, 2019-2025
37 companies · $2,829 in 2025
The $2,829 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2020: $640 · 2021: $1,765 · 2022: $1,595 · 2023: $1,848 · 2024: $2,278 · 2025: $2,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,850 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,849.76 |
| Education | $104.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,198.49 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,207.44 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,197.32 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $1,161.06 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $850.49 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Boston Scientific Corporation | $683.59 | 2021-2025 | General - Biliary Devices |
| Alnylam Pharmaceuticals INC. | $566.01 | 2020-2025 | Givlaari |
| Qol Medical, LLC | $374.19 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $315.82 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $280.55 | 2024-2025 | Zenpep |
| Genzyme Corporation | $277.14 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $249.84 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $241.33 | 2019-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $236.16 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $223.99 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $206.78 | 2021-2024 | Rebyota |
| Nestle Healthcare Nutrition INC. | $198.02 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $190.43 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $175.88 | 2019-2023 | Ocaliva |
| Lilly USA, LLC | $156.59 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $150.43 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $131.96 | 2019-2024 | Dificid |
| Amgen INC. | $104.73 | 2021 | |
| Organon LLC | $89.06 | 2023-2025 | Hadlima, Renflexis |
| Celgene Corporation | $63.67 | 2021-2022 | |
| Intra-Sana Laboratories | $63.50 | 2021-2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Vivus LLC | $60.44 | 2021-2025 | Pancreaze |
| Evoke Pharma, INC. | $52.52 | 2021-2023 | Gimoti |
| Ucb, INC. | $47.44 | 2019 | |
| Redhill Biopharma INC. | $45.04 | 2021-2022 | |
| Celltrion USA INC. | $35.95 | 2023-2025 | Yuflyma, Vegzelma |
| Fresenius Kabi USA, LLC | $35.40 | 2024 | Idacio |
| Braintree Laboratories, INC. | $24.51 | 2021 | |
| Alcresta Therapeutics, INC. | $21.07 | 2024 | Relizorb |
| Alfasigma USA, INC. | $17.31 | 2020 | |
| Covidien LP | $16.03 | 2019 | |
| Shire North American Group INC | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Chiniwalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.